{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:05:03Z","timestamp":1772762703529,"version":"3.50.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Laboratory staff who work with meningococcal isolates are at increased risk for developing invasive disease relative to the general population. This was the first study of laboratory workers who received both a conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Men ACWY-CRM, Menveo) and an investigational multicomponent vaccine against serogroup B containing factor H binding protein, neisserial adhesin A,\n            <jats:italic>Neisseria<\/jats:italic>\n            heparin binding antigen, and New Zealand strain outer membrane vesicles (4CMenB). Healthy adults (18 to 50 years of age) received three doses of 4CMenB at baseline, 2 months, and 6 months followed by a single dose of MenACWY-CRM 1 month later. Immunogenicity was assessed via serum bactericidal assay using human complement (hSBA) at 1 month postvaccination; solicited reactogenicity and adverse events were monitored. Fifty-four participants enrolled. Bactericidal immune responses were evident after each dose of 4CMenB, as assessed by hSBA geometric mean titers and percentages of subjects with hSBA titers of \u22654 against the test strains or a 4-fold rise in titer over baseline. At 1 month postvaccination, most MenACWY-CRM recipients had hSBA titers of \u22658 against serogroups A, C, W-135, and Y. Few participants discontinued due to an adverse event or vaccine reaction. Rates of solicited reactions were lower after MenACWY-CRM than after 4CMenB administration. Sequential administration of 4CMenB and MenACWY-CRM provided robust evidence of an immune response against serogroups A, B, C, W-135, and Y in laboratory workers routinely exposed to meningococcal isolates.\n          <\/jats:p>","DOI":"10.1128\/cvi.00304-10","type":"journal-article","created":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T03:29:26Z","timestamp":1293074966000},"page":"483-486","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":76,"title":["Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM\n            <sub>197<\/sub>\n            Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates"],"prefix":"10.1128","volume":"18","author":[{"given":"Alan","family":"Kimura","sequence":"first","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annett","family":"Kleinschmidt","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.1.332-337.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","volume":"27","year":"2009","unstructured":"Bambini, S., et al. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.","journal-title":"Vaccine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","year":"2006","unstructured":"Borrow, R., et al. 2006. Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","first-page":"130","volume":"4","year":"2001","unstructured":"Boutet, R., J. M. Stuart, D. M. Jones, and E. B. Kaczmarski. 2001. Prevention of meningococcal infection in laboratory workers\u2014an audit of practice in England and Wales. Commun. Dis. Public Health 4:130-132.","journal-title":"Commun. Dis. Public Health"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jama.287.10.1256","volume":"287","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Laboratory-acquired meningococcal disease\u2014United States, 2000. JAMA 287:1256-1258.","journal-title":"JAMA"},{"key":"e_1_3_2_7_2","first-page":"1042","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009 Sep 25. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 58:1042-1043.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","volume":"50","year":"2010","unstructured":"Cohn, A. C., et al. 2010. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50:184-191.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","year":"2010","unstructured":"Donnelly, J., et al. 2010 Nov 9. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","volume":"51","year":"2010","unstructured":"Findlow, J., et al. 2010. Multicentre, open-label, randomised phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","year":"2006","unstructured":"Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","volume":"28","year":"2010","unstructured":"Giuliani, M. M., et al. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030.","journal-title":"Vaccine"},{"key":"e_1_3_2_13_2","first-page":"1","volume":"35","year":"2009","unstructured":"National Advisory Committee on Immunization. 2009. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee statement (ACS). Can. Commun. Dis. Rep. 35(ACS-3):1-40.","journal-title":"Can. Commun. Dis. Rep."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","volume":"25","year":"2007","unstructured":"N\u00f8kleby, H, et al. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25:3080-3084.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","volume":"21","year":"2003","unstructured":"Platonov, A. E., I. V. Vershinina, E. J. Kuijper, R. Borrow, and H. K\u00e4yhty. 2003. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21:4437-4447.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00207-09"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00125-09"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","volume":"29","year":"2010","unstructured":"Siberry, G. K., et al. 2010. Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr. Infect. Dis. J. 29:391-396.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","volume":"29","year":"2010","unstructured":"Snape, M. D., et al. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71-e79.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_20_2","first-page":"173","volume":"299","year":"2008","unstructured":"Snape, M. D., et al. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173-184.","journal-title":"JAMA"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00304-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00304-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:45:03Z","timestamp":1627591503000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00304-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1128\/CVI.00304-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00304-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2010-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}